Twist Bioscience Receives $45.88 Consensus Price Target

Analysts maintain 'Moderate Buy' rating on the synthetic biology company's stock.

Mar. 16, 2026 at 9:54am

Got story updates? Submit your updates here. ›

Twist Bioscience Corporation (NASDAQ:TWST) has received a consensus price target of $45.88 from the nine analysts covering the company, according to Marketbeat Ratings. The analysts have issued a 'Moderate Buy' rating on the stock, with two giving a 'sell' rating and seven issuing 'buy' recommendations.

Why it matters

Twist Bioscience is a leading synthetic biology company that has developed a proprietary platform for high-throughput DNA synthesis. The consensus price target and rating from analysts suggest they see potential upside in the company's stock, despite some concerns.

The details

The average 1-year price target among the analysts covering Twist Bioscience is $45.8750. Several equity research firms have recently weighed in on the stock, with TD Cowen reiterating a 'buy' rating, Weiss Ratings giving a 'sell (d-)' rating, Evercore increasing its price target to $52 and maintaining an 'outperform' rating, and Barclays lifting its price objective to $50 while also rating the stock 'overweight'.

  • Twist Bioscience last posted its quarterly earnings data on February 2, 2026.

The players

Twist Bioscience Corporation

A synthetic biology company specializing in the development and commercialization of DNA-based products and solutions, founded in 2013 and headquartered in South San Francisco, California.

TD Cowen

An investment research firm that has reiterated a 'buy' rating on Twist Bioscience's stock.

Weiss Ratings

A financial research firm that has given Twist Bioscience a 'sell (d-)' rating.

Evercore

An investment bank that has increased its price target on Twist Bioscience to $52 and maintained an 'outperform' rating.

Barclays

A global financial services provider that has lifted its price objective on Twist Bioscience to $50 while also rating the stock 'overweight'.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The consensus price target and rating from analysts suggest they see potential upside in Twist Bioscience's stock, despite some concerns, underscoring the company's position as a leader in the synthetic biology space.